Cargando…

Comparative dosimetrical analysis of intensity-modulated arc therapy, CyberKnife therapy and image-guided interstitial HDR and LDR brachytherapy of low risk prostate cancer

BACKGROUND: The objective of the study was to dosimetrically compare the intensity-modulated-arc-therapy (IMAT), Cyber-Knife therapy (CK), single fraction interstitial high-dose-rate (HDR) and low-dose-rate (LDR) brachytherapy (BT) in low-risk prostate cancer. MATERIALS AND METHODS: Treatment plans...

Descripción completa

Detalles Bibliográficos
Autores principales: Fröhlich, Georgina, Ágoston, Péter, Jorgo, Kliton, Stelczer, Gábor, Polgár, Csaba, Major, Tibor
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Via Medica 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8241303/
https://www.ncbi.nlm.nih.gov/pubmed/34211769
http://dx.doi.org/10.5603/RPOR.a2021.0028
_version_ 1783715384014143488
author Fröhlich, Georgina
Ágoston, Péter
Jorgo, Kliton
Stelczer, Gábor
Polgár, Csaba
Major, Tibor
author_facet Fröhlich, Georgina
Ágoston, Péter
Jorgo, Kliton
Stelczer, Gábor
Polgár, Csaba
Major, Tibor
author_sort Fröhlich, Georgina
collection PubMed
description BACKGROUND: The objective of the study was to dosimetrically compare the intensity-modulated-arc-therapy (IMAT), Cyber-Knife therapy (CK), single fraction interstitial high-dose-rate (HDR) and low-dose-rate (LDR) brachytherapy (BT) in low-risk prostate cancer. MATERIALS AND METHODS: Treatment plans of ten patients treated with CK were selected and additional plans using IMAT, HDR and LDR BT were created on the same CT images. The prescribed dose was 2.5/70 Gy in IMAT, 8/40 Gy in CK, 21 Gy in HDR and 145 Gy in LDR BT to the prostate gland. EQD2 dose-volume parameters were calculated for each technique and compared. RESULTS: EQD2 total dose of the prostate was significantly lower with IMAT and CK than with HDR and LDR BT, D90 was 79.5 Gy, 116.4 Gy, 169.2 Gy and 157.9 Gy (p < 0.001). However, teletherapy plans were more conformal than BT, COIN was 0.84, 0.82, 0.76 and 0.76 (p < 0.001), respectively. The D(2) to the rectum and bladder were lower with HDR BT than with IMAT, CK and LDR BT, it was 66.7 Gy, 68.1 Gy, 36.0 Gy and 68.0 Gy (p = 0.0427), and 68.4 Gy, 78.9 Gy, 51.4 Gy and 70.3 Gy (p = 0.0091) in IMAT, CK, HDR and LDR BT plans, while D(0.1) to the urethra was lower with both IMAT and CK than with BTs: 79.9 Gy, 88.0 Gy, 132.7 Gy and 170.6 Gy (p < 0.001). D(2) to the hips was higher with IMAT and CK, than with BTs: 13.4 Gy, 20.7 Gy, 0.4 Gy and 1.5 Gy (p < 0.001), while D(2) to the sigmoid, bowel bag, testicles and penile bulb was higher with CK than with the other techniques. CONCLUSIONS: HDR monotherapy yields the most advantageous dosimetrical plans, except for the dose to the urethra, where IMAT seems to be the optimal modality in the radiotherapy of low-risk prostate cancer.
format Online
Article
Text
id pubmed-8241303
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Via Medica
record_format MEDLINE/PubMed
spelling pubmed-82413032021-06-30 Comparative dosimetrical analysis of intensity-modulated arc therapy, CyberKnife therapy and image-guided interstitial HDR and LDR brachytherapy of low risk prostate cancer Fröhlich, Georgina Ágoston, Péter Jorgo, Kliton Stelczer, Gábor Polgár, Csaba Major, Tibor Rep Pract Oncol Radiother Research Paper BACKGROUND: The objective of the study was to dosimetrically compare the intensity-modulated-arc-therapy (IMAT), Cyber-Knife therapy (CK), single fraction interstitial high-dose-rate (HDR) and low-dose-rate (LDR) brachytherapy (BT) in low-risk prostate cancer. MATERIALS AND METHODS: Treatment plans of ten patients treated with CK were selected and additional plans using IMAT, HDR and LDR BT were created on the same CT images. The prescribed dose was 2.5/70 Gy in IMAT, 8/40 Gy in CK, 21 Gy in HDR and 145 Gy in LDR BT to the prostate gland. EQD2 dose-volume parameters were calculated for each technique and compared. RESULTS: EQD2 total dose of the prostate was significantly lower with IMAT and CK than with HDR and LDR BT, D90 was 79.5 Gy, 116.4 Gy, 169.2 Gy and 157.9 Gy (p < 0.001). However, teletherapy plans were more conformal than BT, COIN was 0.84, 0.82, 0.76 and 0.76 (p < 0.001), respectively. The D(2) to the rectum and bladder were lower with HDR BT than with IMAT, CK and LDR BT, it was 66.7 Gy, 68.1 Gy, 36.0 Gy and 68.0 Gy (p = 0.0427), and 68.4 Gy, 78.9 Gy, 51.4 Gy and 70.3 Gy (p = 0.0091) in IMAT, CK, HDR and LDR BT plans, while D(0.1) to the urethra was lower with both IMAT and CK than with BTs: 79.9 Gy, 88.0 Gy, 132.7 Gy and 170.6 Gy (p < 0.001). D(2) to the hips was higher with IMAT and CK, than with BTs: 13.4 Gy, 20.7 Gy, 0.4 Gy and 1.5 Gy (p < 0.001), while D(2) to the sigmoid, bowel bag, testicles and penile bulb was higher with CK than with the other techniques. CONCLUSIONS: HDR monotherapy yields the most advantageous dosimetrical plans, except for the dose to the urethra, where IMAT seems to be the optimal modality in the radiotherapy of low-risk prostate cancer. Via Medica 2021-04-14 /pmc/articles/PMC8241303/ /pubmed/34211769 http://dx.doi.org/10.5603/RPOR.a2021.0028 Text en © 2021 Greater Poland Cancer Centre https://creativecommons.org/licenses/by-nc-nd/4.0/This article is available in open access under Creative Common Attribution-Non-Commercial-No Derivatives 4.0 International (CC BY-NC-ND 4.0) license, allowing to download articles and share them with others as long as they credit the authors and the publisher, but without permission to change them in any way or use them commercially
spellingShingle Research Paper
Fröhlich, Georgina
Ágoston, Péter
Jorgo, Kliton
Stelczer, Gábor
Polgár, Csaba
Major, Tibor
Comparative dosimetrical analysis of intensity-modulated arc therapy, CyberKnife therapy and image-guided interstitial HDR and LDR brachytherapy of low risk prostate cancer
title Comparative dosimetrical analysis of intensity-modulated arc therapy, CyberKnife therapy and image-guided interstitial HDR and LDR brachytherapy of low risk prostate cancer
title_full Comparative dosimetrical analysis of intensity-modulated arc therapy, CyberKnife therapy and image-guided interstitial HDR and LDR brachytherapy of low risk prostate cancer
title_fullStr Comparative dosimetrical analysis of intensity-modulated arc therapy, CyberKnife therapy and image-guided interstitial HDR and LDR brachytherapy of low risk prostate cancer
title_full_unstemmed Comparative dosimetrical analysis of intensity-modulated arc therapy, CyberKnife therapy and image-guided interstitial HDR and LDR brachytherapy of low risk prostate cancer
title_short Comparative dosimetrical analysis of intensity-modulated arc therapy, CyberKnife therapy and image-guided interstitial HDR and LDR brachytherapy of low risk prostate cancer
title_sort comparative dosimetrical analysis of intensity-modulated arc therapy, cyberknife therapy and image-guided interstitial hdr and ldr brachytherapy of low risk prostate cancer
topic Research Paper
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8241303/
https://www.ncbi.nlm.nih.gov/pubmed/34211769
http://dx.doi.org/10.5603/RPOR.a2021.0028
work_keys_str_mv AT frohlichgeorgina comparativedosimetricalanalysisofintensitymodulatedarctherapycyberknifetherapyandimageguidedinterstitialhdrandldrbrachytherapyoflowriskprostatecancer
AT agostonpeter comparativedosimetricalanalysisofintensitymodulatedarctherapycyberknifetherapyandimageguidedinterstitialhdrandldrbrachytherapyoflowriskprostatecancer
AT jorgokliton comparativedosimetricalanalysisofintensitymodulatedarctherapycyberknifetherapyandimageguidedinterstitialhdrandldrbrachytherapyoflowriskprostatecancer
AT stelczergabor comparativedosimetricalanalysisofintensitymodulatedarctherapycyberknifetherapyandimageguidedinterstitialhdrandldrbrachytherapyoflowriskprostatecancer
AT polgarcsaba comparativedosimetricalanalysisofintensitymodulatedarctherapycyberknifetherapyandimageguidedinterstitialhdrandldrbrachytherapyoflowriskprostatecancer
AT majortibor comparativedosimetricalanalysisofintensitymodulatedarctherapycyberknifetherapyandimageguidedinterstitialhdrandldrbrachytherapyoflowriskprostatecancer